Published • loading... • Updated
Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
The deal would add Bio-Techne’s multi-omics and precision diagnostics tools and is expected to generate about 140 million euros in annual cost savings.
- On Thursday, June 25, 2026, Merck KGaA, Darmstadt, Germany, announced a definitive agreement to acquire Minneapolis-based Bio-Techne Corporation for $11.3 billion in an all-cash deal priced at $73 per share.
- The acquisition strengthens Merck KGaA's position in high-growth life sciences markets including multi-omics, spatial biology, and cell and gene therapy while adding complementary research and bioprocessing capabilities.
- Merck KGaA expects annual cost synergies of about 140 million euros fully realized by year 3 post-closing. The transaction is expected to close by late 2026 or early 2027, subject to regulatory approval.
- Bio-Techne President and Chief Executive Officer Kim Kelderman called the deal "a testament to the remarkable company our team has built," noting it will provide greater scale to accelerate innovation.
- The deal follows large healthcare transactions this year, including Danaher's $9.9 billion acquisition of Masimo in February, as medical technology and life sciences firms seek to broaden product offerings and gain market share.
Insights by Ground AI
18 Articles
18 Articles
The pharmaceutical and technology group is taking the next acquisition under its new boss Kai Beckmann. Merck is to advance the billion deal in the laboratory business with pharmaceutical customers and researchers.
Coverage Details
Total News Sources18
Leaning Left3Leaning Right2Center4Last UpdatedBias Distribution45% Center
Bias Distribution
- 45% of the sources are Center
45% Center
L 33%
C 45%
R 22%
Factuality
To view factuality data please Upgrade to Premium
